News & Updation
Best Paper Awards
World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.
Best Article of current issue
Download Article : Click here
PROGNOSTIC VALUE OF SERUM LDH AT DIAGNOSIS IN PATIENTS WITH MULTIPLE MYELOMA
Hashem Abdulaziz Hashem*, Firas Hussein and Mohammad Imad Khaiat
Background: Multiple myeloma (MM) is a malignant disorder of clonal plasma cells. A number of biological factors influence the evolution of patients with MM. Objective: the present study aims to evaluate the prognostic value of serum lactate dehydrogenase (LDH) at diagnosis in terms of survival of patients with MM and response to treatment. Materials and Methods: This is prognostic study conducted in the Department of Oncology in Tishreen University Hospital –Lattakia- Syria between January 2006 and January 2016. Patients who newly diagnosed with MM were included in the study. Results: A total of 120 patients with MM were included in the study. The median age was 60.5 years and 55% were men. Arate of 48.3% of patients were in stage II, and 72.5% of cases were secreted of IgG. The response to therapy was complete in 16 % of patients with elevated level of LDH versus 44.3% in normal LDH group (p<0.05), and refractory to therapy was more frequently in elevated LDH group (36% vs. 2.9%, p:0.001). Median overall survival(OS), progression –free survival(PFS) were 65.3±32.9 ,36.3±21.5 months respectively in normal LDH group versus 36.7±20.4 , 16.06±17.4 months respectively in elevated LDH group (p:0.0001). High level of LDH, creatinine, and stage III were independent adverse prognostic parameters for both OS and PFS (p<0.05). Conclusion: High level of LDH is a negative prognostic factor in evolution of MM patients, adversely influencing therapeutic response rates and reducing the survival of patients with MM.[Full Text Article]